The cascade of care for hepatitis B – any lessons from the HIV field?
The WHO has called for eliminating both HIV and HBV as public health threats by 2030. Whereas the cascade of care for HIV is well rolled out at 80-80-80%s (diagnosed- treated-suppressed), rates are significantly lower for chronic hepatitis B (13-3-?), with only 7 million people treated. Major gaps exist at different stages of the hepatitis B cascade. There is a need to expand HBV vaccination and screening, as well as improve linkage to care and monitoring. Antiviral treatment should be provided earlier.
Authors
- Vincent Soriano (ORCID: https://orcid.org/0000-0002-4624-5199)
- Carmen Alvarez-Domı́nguez (ORCID: https://orcid.org/0000-0002-4585-6959)
- Carmen de Mendoza (ORCID: https://orcid.org/0000-0001-5224-7492)
- Octavio Corral (ORCID: https://orcid.org/0000-0002-6756-4631)
- Víctor Moreno‐Torres (ORCID: https://orcid.org/0000-0002-9798-4514)
- Pablo Barreiro
Institutions
- Hospital Universitario La Paz (ES)
- Universidad Internacional De La Rioja (ES)
Publication Details
- Journal
- Expert Review of Anti-infective Therapy
- Published
- 2025-10-26
- DOI
- https://doi.org/10.1080/14787210.2025.2580455
- Citations
- 2
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71